Skip to content Skip to navigation

Development and validation of selective novel small molecule therapeutics for Parkinson's Disease

Cannabinoid receptor
selvanegra/iStock

Project Summary

Parkinson’s disease is the second most common neurodegenerative disorder, affecting a million people or more in America alone. Many lines of evidence point to a role of inflammation and the immune system in triggering neurodegeneration and disease progression.

This team will use their Neuroscience:Translate award to develop small-molecule therapeutics with immunomodulatory properties linked to Parkinson’s disease and test their potentially therapeutic effects in cell cultures and animal models of the disease.

Participants

Team Members:

Jennifer Lin, PhD, Research Engineer, Bioengineering
Mike Jaime, Finance Manager

Funding Type: 
Neuroscience:Translate
Round: 
4
Award Year: 
2022